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Abstract: RUNX1 overlapping RNA (RUNXOR) is a long non-coding RNA and plays a pivotal
role in the differentiation of myeloid cells via targeting runt-related transcription factor 1 (RUNX1).
We and others have previously reported that myeloid-derived suppressor cells (MDSCs) expand and
inhibit host immune responses during chronic viral infections; however, the mechanisms responsible
for MDSC differentiation and suppressive functions, in particular the role of RUNXOR–RUNX1,
remain unclear. Here, we demonstrated that RUNXOR and RUNX1 expressions are significantly
upregulated and associated with elevated levels of immunosuppressive molecules, such as arginase
1 (Arg1), inducible nitric oxide synthase (iNOS), signal transducer and activator of transcription
3 (STAT3), and reactive oxygen species (ROS) in MDSCs during chronic hepatitis C virus (HCV)
infection. Mechanistically, we discovered that HCV-associated exosomes (HCV-Exo) can induce the
expressions of RUNXOR and RUNX1, which in turn regulates miR-124 expression via STAT3 signaling,
thereby promoting MDSC differentiation and suppressive functions. Importantly, overexpression
of RUNXOR in healthy CD33+ myeloid cells promoted differentiation and suppressive functions of
MDSCs. Conversely, silencing RUNXOR or RUNX1 expression in HCV-derived CD33+ myeloid cells
significantly inhibited their differentiation and expressions of suppressive molecules and improved
the function of co-cultured autologous CD4 T cells. Taken together, these results indicate that the
RUNXOR–RUNX1–STAT3–miR124 axis enhances the differentiation and suppressive functions of
MDSCs and could be a potential target for immunomodulation in conjunction with antiviral therapy
during chronic HCV infection.
Keywords: HCV; immune suppression; MDSCs; miR124; RUNXOR; RUNX1
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1. Introduction
Hepatitis C virus (HCV) can employ different strategies to evade host immunity and harness virus
persistence, thus serving as an excellent model for studying the mechanisms of virus-mediated host
immune dysfunction and viral persistence in humans [1,2]. While direct-acting antivirals (DAA) can
efficiently clear HCV infection in the majority of treated individuals, this therapeutic cocktail faces new
issues, such as viral mutation, relapse, and reinfection after treatment [3,4]. In addition, “virological
cure” does not always lead to “immunological cure”, and some immune disorders persist after DAA
treatment with sustained virological response (SVR) [5]. The failure to manage many chronic infectious
diseases, including HCV, stems from our incomplete understanding of the pathogen–host interactions
that can dysregulate host immune responses.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid
cells produced during aberrant myelopoiesis under pathogenic conditions, such as cancer and
inflammatory or infectious diseases [6–8]. MDSCs have gained special attention due to their role in
suppressing host immune responses [9,10]. MDSCs contribute to immune homeostasis via limiting
excessive inflammatory processes, but their expansion may be at the expense of pathogen elimination,
resulting in persistent infection [8]. We and others reported that MDSCs expand and inhibit T cell
functions in multiple disease models, including chronic viral (HCV and HIV) infections [11–18].
However, the mechanisms responsible for MDSC differentiation and suppressive functions during
viral infection remain unclear.
Long non-coding RNAs (lncRNAs) are genomic transcripts of non-coding RNAs consisting of
both lncRNA (>200 nt in length) and miRNAs (~20 nt) and possess regulatory functions [19–21].
Thus far, thousands of lncRNAs have been discovered, but most of their functions have not been
characterized [22]. Recent studies suggest that lncRNAs are involved in almost all cellular processes via
a variety of mechanisms [23–27], and their expressions are species-, cell-, and disease-specific [19–21].
RUNXOR is a 260-kb un-spliced lncRNA that interacts epigenetically with multiple sites within
the RUNX1 locus [28]. RUNX1 is a tumor suppressor gene responsible for modulating various
hematopoietic regulators. RUNXOR regulates the expression of RUNX1 in acute myeloid leukemia
(AML) cells by binding to its promoter and enhancer [29]. It may also be involved in chromosomal
translocation that normally occurs during malignancies [28]. RUNXOR can directly bind to chromatin,
resulting in the formation of a long-range intra-chromosomal loop, which is a typical epigenetic
mechanism employed by a regulatory element so that it can regulate expression of genes that are
distantly located [29,30]. Recently, the RUNXOR–RUNX1 axis has been shown to be associated with
the development of MDSCs in lung cancer [30].
Exosomes are membrane-bound extracellular microvesicles that serve as carriers to transfer
various signaling molecules (such as viral RNA, mRNA, or ncRNA) between cells without any direct
cell-to-cell contact, and play an important role in regulating immune responses [31–34]. Exosomes
are produced and secreted by all types of cells and importantly, exhibit enrichment of the human
tetraspanin CD81, a receptor for the HCV E2 glycoprotein [35]. Infected hepatocytes release HCV
genomic materials into the peripheral blood in the form of circulating exosomes that exploit the
fusogenic capabilities of exosomes with other cells, transmitting HCV-RNA and thereby dysregulating
host immune responses, even in the presence of neutralizing antibodies [36–38]. We previously showed
that exosomes isolated from the plasma of HCV patients contain HCV-RNAs and were able to promote
MDSC expansion thereby inhibiting T cell function [18]. Whether HCV RNA-associated exosomes
(HCV-Exo) can promote MDSC expansion and suppression through regulation of RUNXOR–RUNX1
expression has yet to be determined.
In this study, we characterized the expression and role of RUNXOR and RUNX1 in MDSC
expansion and function during HCV infection. We demonstrated that the expressions of RUNXOR
and RUNX1 are upregulated and play a role in driving MDSC expansion through regulating STAT3
and miR-124 expressions during HCV infection. We also discovered that HCV-Exo dysregulate
the RUNXOR–RUNX1–STAT3–miR-124 axis, thus playing an important role in regulating MDSC
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expansion and their immunosuppressive functions. Our study reveals a novel mechanism of immune
dysregulation during chronic viral infection.
2. Materials and Methods
2.1. Subjects
The study subjects were composed of two populations: 50 chronically HCV-infected individuals
and 54 healthy subjects (HS). HCV genotype (70% type 1, 30% type 2 or 3) and viral load (ranging
17,000–17,000,000 IU/mL) were determined by Lexington VAMC, and all subjects were virologically
and serologically positive for HCV prior to antiviral treatment. Healthy subjects were negative for
HBV, HCV, and HIV infections and were recruited by BioIVT (Gray, TN, USA). The characteristics of
the subjects recruited in this study are described in Table 1.
Table 1. Demographic information of the study participants.
Subjects

Numbers

Age (Mean)

Gender (M/F)

Viral Load and Other Characteristics

HCV
HS

50
54

29–65 (46)
22–64 (33)

39/11
41/13

17,000–17,000,000 IU/mL, 36GT1, 8GT2, 6GT3
All the tested negative for HCV, HBV and HIV

2.2. Cell Isolation, Culture, and Flow Cytometric Analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using Ficoll density
gradients (GE Healthcare, Piscataway, NJ, USA). CD33+ cells were isolated from PBMCs using a CD33+
Cell Isolation Kit and a MidiMACS™ Separator column (Miltenyi Biotec, Auburn, CA, USA). The cells
were cultured in RPMI 1640 medium with 10% fetal bovine serum (Atlanta Biologicals, Flowery
Branch, GA, USA), 100 IU/mL penicillin, and 2 mM L-glutamine (Thermo Scientific, Logan, UT, USA)
at 37 ◦ C and 5% CO2 atmosphere. Cell depletion and culture with exosomes were carried out as
described previously [15–18]. Flow cytometry analysis of cell phenotypes and intracellular cytokines in
PBMCs was carried out as described previously [16–18]. Anti-CD4-FITC, anti-IFN-γ-PE, anti-CD33-PE,
anti-CD14-APC (Biolegend), anti-HLA-DR-FITC, anti-CD3-APC, anti-Arg1-PE, anti-pSTAT3-PerCP
(all from Biolegend, San Diego, CA, USA) and anti-iNOS-PE (Novus biologicals, Centennial, CO,
USA) reagents were used along with isotype control antibodies (BD Bioscience, San Jose, CA, USA).
Levels of reactive oxygen species (ROS) in myeloid cells were measured using the H2DCFDA-based
kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. The stained cells were
acquired on an AccuriTM C6 flow cytometer (BD, Franklin Lakes, NJ, USA) and analyzed using FlowJo
software (Tree Star, Ashland, OR). Isotype control antibodies (eBioscience, San Diago, CA, USA) and
fluorescence minus one (FMO) controls were used to determine the background levels of staining and
adjust multicolor compensation as a gating strategy.
2.3. Exosome Isolation and Purification
Plasma was purified from 50 mL of whole blood from the research subjects and filtered to exclude
particles larger than 0.8 µm, using syringe filters (Millex-AA Cat #: SLAA033SS, Millipore, Billerica,
MA, USA). Exosomes were then isolated from plasma by a differential centrifugation method as
previously described [18].
2.4. lncRNA and miRNA Arrays and RT-qPCR Validation
CD33+ myeloid cells were purified from PBMCs as described above. Total cellular RNA from
CD33+ cells (pooled from 6 chronic HCV patients and 6 HS) was isolated using the miRNeasy Mini kit
(Qiagen, Valencia, CA, USA). The RNA quality and quantity were analyzed using a BioPhotometer
spectrophotometer UV/VIS, and RNA integrity was determined using gel electrophoresis. LncRNAs
were analyzed using the Arraystar gene array service (Rockville, MD. The miScript miRNA array was
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performed by Qiagen [17]. To validate the results for up- or downregulated miRNAs by real-time
RT-PCR, cDNA was generated from total RNA by the Taqman advanced miRNA cDNA synthesis
kit and the High-Capacity cDNA Reverse Transcription Kit (Thermo Scientific, Logan, UT, USA).
The miRNA expression levels were assessed by RT-qPCR using Taqman® fast advanced master mix
(Thermo Scientific) and the CFX96TM RT-PCR Detection System (Bio-Rad Laboratories, Hercules, CA,
USA). The miRNA levels were determined using the 2−∆∆ct relative quantification method and were
normalized to U6 RNA (SNORD61) level as an internal control.
2.5. Transfection and Co-Culture Experiments
For miR-124 inhibition, CD33+ cells isolated from PBMCs of HS were transfected with 30 pmol of
miR-124 inhibitor or negative control inhibitor. For miR-124 overexpression, CD33+ cells isolated from
PBMCs of HCV subjects were transfected with 30 pmol of miR-124 mimic or negative control mimic.
For STAT3 knockdown, the CD33+ cells were transfected with 50 nM of a STAT3 SMART pool of siRNAs
or a pool of scrambled siRNAs. For RUNXOR and RUNX1 knockdown, the cells were transfected with
50 nM of a RUNXOR SMART pool siRNAs, a RUNX1 SMART pool siRNAs, or a pool of scrambled
siRNA (Lafayette, CO, USA). RUNXOR was overexpressed by using a Cas9-gRNA-RUNXOR promoter
targeting vector and a RUNXOR Arm-pCMV-puromycin donor vector (kindly provided by Dr. Hu,
Stanford University Medical School, CA). The transfection of miRNA or siRNA was performed using
the Human Monocyte Nucleofector Kit and Nucleofector II Device (Lonza, Allendale, NJ, USA)
following the manufacturer’s instructions. The transfected cells were cultured for two days in IMEM
medium (Lonza) with 10% FBS. The cells were analyzed by flow cytometry or RT-qPCR as described
above. For CD4+ T cell co-culture, autologous CD4+ T cells were stimulated with anti-CD3 (1 µg/mL)
and anti-CD28 (2 µg/mL (BD Bioscience) for two days in IMEM complete medium, followed by adding
the transfected CD33+ cells (at 1:2 ratio) for another three days.
2.6. Statistical Analysis
The parametric data are presented as mean ± SEM. Comparisons between two groups were
analyzed using the unpaired t-test with Welch’s correction after checking the value of the F-test.
One-tail paired t-test was used to compare two groups, and their associations were analyzed by
Pearson correlation. The nonparametric data are presented as median with interquartile range and
were analyzed by a one-tail Mann–Whitney test and then analyzed by Spearman correlation. p-values
< 0.05 or p < 0.01 were considered significant or very significant, respectively.
3. Results
3.1. MDSCs Accumulate in Peripheral Blood during Chronic HCV Infection
MDSCs play an important role in disease progression by suppressing host immune responses [6–8,39].
Human MDSCs are immature myeloid cell phenotyped as CD33+ HLA-DR−/low , which can be further
categorized into monocytic MDSCs (M-MDSCs) and granulocytic MDSCs (G-MDSCs) based on the level
of expression of the monocytic marker CD14 [40,41]. To investigate the role and mechanisms of MDSC
differentiation and functions during viral infection, we analyzed the frequencies of MDSCs within
PBMCs from patients with chronic HCV infection compared to HS using flow cytometry. We found
that the frequencies of total MDSCs (CD33+ HLA-DR−/low ), M-MDSCs (CD33+ HLA-DR−/low CD14+ ),
and G-MDSCs (CD33+ HLA-DR−/low CD14− ) were significantly increased in PBMCs in individuals
with chronic HCV infection (Figure 1A–C).
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3.2. RUNXOR and RUNX1 Are Upregulated in MDSCs during Chronic HCV Infection
3.2. RUNXOR and RUNX1 Are Upregulated in MDSCs during Chronic HCV Infection
To determine whether lncRNAs play a role in MDSC expansion during HCV infection, we analyzed
To determine whether lncRNAs play a role in MDSC expansion during HCV infection, we
the transcripts of lncRNAs and messenger RNAs (mRNAs) in MDSCs isolated from HCV-infected
analyzed the transcripts of lncRNAs and messenger RNAs (mRNAs) in MDSCs isolated from HCVindividuals and HS using the Arraystar gene expression array. Among the lncRNAs analyzed (shown as
infected individuals and HS using the Arraystar gene expression array. Among the lncRNAs
scatter plot in Figure 1D), 545 lncRNAs (red dots) were upregulated (>2-fold), 192 lncRNAs (green dots)
analyzed (shown as scatter plot in Figure 1D), 545 lncRNAs (red dots) were upregulated (>2-fold),
were downregulated (>2-fold), and 27,754 lncRNAs (black dots) remained unchanged in MDSCs from
192 lncRNAs (green dots) were downregulated (>2-fold), and 27,754 lncRNAs (black dots) remained
HCV patients compared to HS. Given the critical role of RUNXOR in myeloid cell maturation [28–30],
unchanged in MDSCs from HCV patients compared to HS. Given the critical role of RUNXOR in
we further analyzed RUNXOR expression in the array and validated the results by real-time RT-qPCR,
myeloid cell maturation [28–30], we further analyzed RUNXOR expression in the array and validated
which revealed a >4-fold increase in MDSCs derived from HCV-infected individuals compared to HS
the results by real-time RT-qPCR, which revealed a >4-fold increase in MDSCs derived from HCV(Figure 1E).
infected individuals compared to HS (Figure 1E).
For mRNA expression analysis (shown as scatter plot in Figure 1F), 154 mRNAs (red dots) were
For mRNA expression analysis (shown as scatter plot in Figure 1F), 154 mRNAs (red dots) were
upregulated, 74 mRNAs (green dots) were downregulated, and 18,187 mRNA transcripts remained
upregulated, 74 mRNAs (green dots) were downregulated, and 18,187 mRNA transcripts remained
unchanged. Notably, the mRNA array analysis revealed an upregulation of RUNX1 in myeloid cells
unchanged. Notably, the mRNA array analysis revealed an upregulation of RUNX1 in myeloid cells
derived from HCV subjects, which was validated by RT-qPCR assay (Figure 1G). Importantly, the
derived from HCV subjects, which was validated by RT-qPCR assay (Figure 1G). Importantly, the
expression levels of RUNXOR and RUNX1 positively correlated with each other, as determined by
expression levels of RUNXOR and RUNX1 positively correlated with each other, as determined by
Spearman correlation (Figure 1H). Taken together, these results suggest that expressions of RUNXOR
Spearman correlation (Figure 1H). Taken together, these results suggest that expressions of RUNXOR
and its target gene RUNX1 are concurrently upregulated and may serve as a biomarker for MDSC
and its target gene RUNX1 are concurrently upregulated and may serve as a biomarker for MDSC
expansion during chronic HCV infection.
expansion during chronic HCV infection.
3.3. Immunosuppressive Molecules Are Elevated in MDSCs during Chronic HCV Infection
3.3. Immunosuppressive Molecules Are Elevated in MDSCs during Chronic HCV Infection
MDSCs suppress host immune responses by producing immunosuppressive mediators, such
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signal
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transcription 3 (STAT3), and reactive oxygen species (ROS) [17–20,42,43]. To determine the molecular
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3.4. MiR-124 Expression Negatively Correlates with STAT3 Levels in MDSCs during HCV Infection
3.4. MiR-124 Expression Negatively Correlates with STAT3 Levels in MDSCs during HCV Infection
We and others previously showed that miRNAs are involved in myelopoiesis orchestrated
We and others previously showed that miRNAs are involved in myelopoiesis orchestrated
through the expressions of cytokine receptors and transcription factors [8,23,44,45]. To identify specific
through the expressions of cytokine receptors and transcription factors [8,23,44,45]. To identify
miRNAs that could affect myelopoiesis during HCV infection, we profiled miRNA expressions in
specific miRNAs that could affect myelopoiesis during HCV infection, we profiled miRNA
MDSCs isolated from HCV patients and HS. Among the miRNAs analyzed, 6 were significantly
expressions in MDSCs isolated from HCV patients and HS. Among the miRNAs analyzed, 6 were
upregulated, 6 were downregulated, and 362 miRNAs remained unchanged in MDSCs from HCV
significantly upregulated, 6 were downregulated, and 362 miRNAs remained unchanged in MDSCs
patients compared to HS [17]. Among the miRNAs that were significantly downregulated, miR-124
from HCV patients compared to HS [17]. Among the miRNAs that were significantly downregulated,
was significantly inhibited (Figure 2L), and its level negatively correlated with STAT3 expression
miR-124 was significantly inhibited (Figure 2L), and its level negatively correlated with STAT3
(Figure 2M), as determined by RT-qPCR. While miR-124 showed a negative correlation with RUNXOR,
expression (Figure 2M), as determined by RT-qPCR. While miR-124 showed a negative correlation
RUNX1, Arg1, and iNOS, there were no significant differences between their expression levels (data not
with RUNXOR, RUNX1, Arg1, and iNOS, there were no significant differences between their
shown). Since the STAT3 level positively correlated with the expression of RUNXOR as well as RUNX1
expression levels (data not shown). Since the STAT3 level positively correlated with the expression
(Figure 2H,K), and, since our previous studies revealed a regulatory role for miR-124/STAT3 pathway
of RUNXOR as well as RUNX1 (Figure 2H,K), and, since our previous studies revealed a regulatory
role for miR-124/STAT3 pathway in MDSC development during HCV infections [18], these new
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in MDSC development during HCV infections [18], these new findings suggest a link between the
findings suggest a axis
link and
between
the RUNXOR/RUNX1
the play
STAT3/miR-124
pathway
RUNXOR/RUNX1
the STAT3/miR-124
pathwayaxis
thatand
could
an important
role in that
the
could
play
an
important
role
in
the
regulation
of
MDSCs
during
chronic
HCV
infection.
regulation of MDSCs during chronic HCV infection.

3.5. RUNXOR
RUNXORand
andRUNX1
RUNX1Regulate
RegulateEach
EachOther’s
Other’sand
andControl
ControlmiR-124
miR-124Expression
Expressionvia
viathe
theSTAT3
STAT3
3.5.
Signaling
in
MDSCs
during
HCV
Infection
Signaling in MDSCs during HCV Infection
To
elucidate
the cause–effect
relationships
betweenbetween
RUNXOR/RUNX1
and miR-124/STAT3
Tofurther
further
elucidate
the cause–effect
relationships
RUNXOR/RUNX1
and miR+
+
expressions
MDSCs, HCV-derived
CD33 cells were
transfected
withtransfected
RUNXOR or
RUNX1
siRNA,
124/STAT3 in
expressions
in MDSCs, HCV-derived
CD33
cells were
with
RUNXOR
or
respectively,
followed
by measuring
theirby
expression
by their
RT-qPCR.
As shown
in Figure 3A,
RUNX1 siRNA,
respectively,
followed
measuring
expression
by RT-qPCR.
AsRUNXOR
shown in
levels
two days post-transfection
siRNA. Interestingly,
Figurewere
3A,significantly
RUNXOR downregulated
levels were significantly
downregulatedwith
twoRUNXOR
days post-transfection
with
silencing
downregulated
the RUNX1
expression
RUNXOR in these
cells. Similarly,
silencing
RUNXORRUNX1
siRNA.also
Interestingly,
silencing
alsoofdownregulated
the expression
of RUNXOR
in
RUNXOR
or
RUNX1
downregulated
the
expression
of
RUNX1
(Figure
3B),
indicating
a
positive
these cells. Similarly, silencing RUNXOR or RUNX1 downregulated the expression of RUNX1 (Figure
feedback
loop between
these
two regulatory
molecules.
Silencing
RUNXOR
expression
3B), indicating
a positive
feedback
loop between
these two
regulatory
molecules.
Silencingattenuated
RUNXOR
the
upregulation
of Arg1,
and STAT3
and increased
Only STAT3
levellevels.
was
expression
attenuated
the iNOS,
upregulation
of Arg1,
iNOS, andmiR-124
STAT3 levels.
and increased
miR-124
significantly
changed
upon
RUNXOR
silencing,
whereas
the
levels
of
these
molecules
were
all
Only STAT3 level was significantly changed upon RUNXOR silencing, whereas the levels of these
significantly
altered
by silencing altered
RUNX1by
expression
molecules were
all significantly
silencing (Figure
RUNX13C–F).
expression (Figure 3C–F).

+
Figure
Figure 3.3. Silencing
Silencing or
or Ectopic
Ectopic expression
expression of
of RUNXOR
RUNXOR or
or RUNX1
RUNX1 in
in CD33
CD33+ cells
cells affects
affects MDSC
MDSC
differentiation
and
immunosuppressive
functions.
(A,B)
RUNXOR
or
RUNX1
expressions
in
differentiation and immunosuppressive functions. (A,B) RUNXOR or RUNX1 expressions in HCV+
HCV-CD33
cells transfected
by control,
RUNXOR,
or RUNX1
siRNA, determined
by RT-qPCR.
real-time
CD33+ cells transfected
by control,
RUNXOR,
or RUNX1
siRNA, determined
by real-time
+ cells transfected with
RT-qPCR.
(C–F)
Arg1,
iNOS,
STAT3,
and
miR-124
expressions
in
HCV-CD33
+
(C–F) Arg1, iNOS, STAT3, and miR-124 expressions in HCV-CD33 cells transfected with control,
control,
RUNXOR,
or RUNX1
siRNA,
determined
by real-time
RT-qPCR.
(G–L)
Ectopic
expression
RUNXOR,
or RUNX1
siRNA,
determined
by real-time
RT-qPCR.
(G–L)
Ectopic
expression
of
of
RUNXOR
promotes
RUNXOR,
RUNX1,
Arg1,
iNOS,
and
STAT3
mRNA
expressions
and
RUNXOR promotes RUNXOR, RUNX1, Arg1, iNOS, and STAT3 mRNA expressions and reduces
reduces
+
+
miR-124
miR-124levels
levelsin
inCD33
CD33+ myeloid
myeloid cells.
cells. (M–Q)
(M–Q) Overexpression
Overexpression of
ofRUNXOR
RUNXORininhealthy
healthyCD33
CD33+cells
cells
enhances
Arg1,
iNOS,
and
pSTAT3
protein
expressions,
increases
ROS
productions,
and
promotes
enhances Arg1, iNOS, and pSTAT3 protein expressions, increases ROS productions, and promotes
−/low CD33+ ) differentiation into MDSCs, as determined by flow
immature
+) differentiation into MDSCs, as determined by flow
immature myeloid
myeloidcells
cells(HLA-DR
(HLA-DR−/low CD33
cytometry
analysis.
cytometry analysis.

To further demonstrate the relationships between RUNXOR/RUNX1 and miR-124/STAT3, CD33+
To further demonstrate the relationships between RUNXOR/RUNX1 and miR-124/STAT3,
cells from
HS were transfected with a RUNXOR CRISPR-Cas9 overexpression system, and the levels of
CD33+ cells from HS were transfected with a RUNXOR CRISPR-Cas9 overexpression system, and the
RUNXOR, miR-124, and mRNAs of RUNX1, Arg1, iNOS, and STAT3 were measured as described above.
levels of RUNXOR, miR-124, and mRNAs of RUNX1, Arg1, iNOS, and STAT3 were measured as
As shown in Figure 3G–L, overexpression of RUNXOR significantly increased the mRNA expressions
described above. As shown in Figure 3G–L, overexpression of RUNXOR significantly increased the
of RUNXOR, RUNX1, Arg1, iNOS, and STAT3, but reduced the level of miR-124. Flow cytometry
mRNA expressions of RUNXOR, RUNX1, Arg1, iNOS, and STAT3, but reduced the level of miR-124.
Flow cytometry analysis revealed that the mean fluorescence intensity (MFI) of Arg1, iNOS, and
pSTAT3 protein levels, and production of ROS were also upregulated by the ectopic expression
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and production of ROS were also upregulated by the ectopic expression RUNXOR in healthy CD33+
+ cells (Figure 3M–P). Most importantly, overexpressing
RUNXOR
healthy
CD33
RUNXOR
in
cells
(Figurein3M–P).
Most
importantly,
overexpressing RUNXOR in healthy CD33+ cells also
resulted
−/low
+
−/low
healthy
CD33 increase
cells alsoinresulted
in a significant
increase immature
in the frequency
of HLA-DR
immature
in
a significant
the frequency
of HLA-DR
(suppressive)
cell subset
within
+ cell population (Figure 3Q). These results demonstrate that
(suppressive)
subset within
the
CD33
the
CD33+ cell cell
population
(Figure
3Q).
These
results demonstrate that RUNXOR regulates the MDSC
RUNXOR regulates
the MDSC
development
and functions
by modulating
the To
expression
of
development
and functions
by modulating
the expression
of suppressive
molecules.
investigate
suppressive
molecules.
To investigate
miR-124
regulatesinRUNXOR
RUNX1 expressions
whether
miR-124
regulates
RUNXOR whether
and RUNX1
expressions
MDSCs, and
we transfected
healthy
+ cells we
+ cells with miR-124 inhibitor and measured the expressions
in MDSCs,
transfected
healthy CD33
CD33
with
miR-124 inhibitor
and measured
the expressions of these molecules. As shown in
of these
molecules.
As shown
in Figurewas
4A–C,
while miR-124
expression
was
significantly
inhibited,
Figure
4A–C,
while miR-124
expression
significantly
inhibited,
RUNXOR
and
RUNX1 expressions
RUNXOR
and RUNX1
expressions
were alterations
only slightly
upregulated,
and these
alterations
were we
not
were
only slightly
upregulated,
and these
were
not significantly
different.
In parallel,
+
+ cells derived
significantly
different.
In
parallel,
we
increased
miR-21
levels
by
transfecting
CD33
increased miR-21 levels by transfecting CD33 cells derived from HCV patients with miR-124 mimic
from
HCV
patientsthe
with
miR-124 mimic
and
then measured
the expressions
of these
molecules.
As
and
then
measured
expressions
of these
molecules.
As shown
in Figure 4D–F,
while
the level of
shown inwas
Figure
4D–F, while
the levelRUNXOR
of miR-124and
wasRUNX1
significantly
RUNXOR and
RUNX1
miR-124
significantly
increased,
levelsincreased,
were not significantly
changed
levels
were overexpression.
not significantly These
changed
by miR-124
suggest target
that miR-124
by
miR-124
results
suggestoverexpression.
that miR-124 is These
likely results
a downstream
of the
is likely a downstream
target
of the RUNXOR–RUNX1
pathway could
in MDSCs,
because
RUNXOR–
RUNXOR–RUNX1
pathway
in MDSCs,
because RUNXOR–RUNX1
regulate
miR-124
but not
RUNX1
could regulate miR-124 but not vice versa.
vice
versa.

Figure
4. RUNXOR
The RUNXOR
and RUNX1
expressions
correlate
with
the STAT3–miR124
in MDSCs
Figure
4. The
and RUNX1
expressions
correlate
with the
STAT3–miR124
axis inaxis
MDSCs
during
+ cells significantly reduces the level
during
HCV
infection.
(A–C)
Silencing
miR-124
in
HS-CD33
+
HCV infection. (A–C) Silencing miR-124 in HS-CD33 cells significantly reduces the level of miR-124 but
miR-124
but onlyRUNXOR
slightly increases
RUNXOR
and RUNX1
(D–F)ofOverexpression
of
onlyofslightly
increases
and RUNX1
expressions.
(D–F)expressions.
Overexpression
miR-124 in HCV+ cells significantly increases miR-124 levels but does not affect RUNXOR and
miR-124
in
HCV-CD33
CD33+ cells significantly increases miR-124 levels but does not affect RUNXOR and RUNX1 expressions.
+
RUNX1
expressions.
(G–L) Silencing
STAT3+ expression
in HCV-CD33
significantly
decreases
(G–L)
Silencing
STAT3 expression
in HCV-CD33
cells significantly
decreasescells
STAT3
level, increases
miRSTAT3
level,
increases
miR-124
expression,
and
inhibits
RUNXOR,
RUNX1,
Arg1,
and
iNOS
mRNA
124 expression, and inhibits RUNXOR, RUNX1, Arg1, and iNOS mRNA expressions (I–L).
expressions (I–L).

To determine whether RUNXOR regulates miR-124 via STAT3 signaling in MDSCs, we silenced
To determine whether RUNXOR
regulates miR-124 via STAT3 signaling in MDSCs, we silenced
STAT3 expression in CD33+ cells from HCV patients and measured the expressions of RUNXOR,
STAT3 expression in CD33+ cells from HCV patients and measured the expressions of RUNXOR,
RUNX1, and those suppressive molecules. Indeed, silencing STAT3 with siRNA significantly reduced
RUNX1, and those suppressive molecules. Indeed, silencing STAT3 with siRNA significantly reduced
STAT3 expression (Figure 4G) but upregulated the expression of miR-124 significantly (Figure 4H),
STAT3 expression (Figure 4G) but upregulated the expression of miR-124 significantly (Figure 4H),
which is in line with our previous report that STAT3 negatively regulates miR-124 expression in
which is in line with our previous report that STAT3 negatively regulates miR-124 expression in
MDSCs [16]. Interestingly, silencing STAT3 expression also reduced the levels of RUNXOR, RUNX1,
MDSCs [16]. Interestingly, silencing STAT3 expression also reduced the levels of RUNXOR, RUNX1,
Arg1, and iNOS expressions (Figure 4I–L), indicating an important positive feedback loop involving
Arg1, and iNOS expressions (Figure 4I–L), indicating an important positive feedback loop involving
STAT3 in the regulation of the RUNXOR–RUNX1–miR-124 axis and MDSC suppressive functions
STAT3 in the regulation of the RUNXOR–RUNX1–miR-124 axis and MDSC suppressive functions
during HCV infection. Taken together, these results suggest that RUNXOR and RUNX1 positively
regulate each other to control the expression of STAT3–miR-124 and immunosuppressive molecules
in MDSCs. While STAT3, but not miR-124, can regulate the RUNXOR–RUNX1 axis in a positive
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regulate each other to control the expression of STAT3–miR-124 and immunosuppressive molecules in
feedback
and
regulate
miR-124
this regulatory
acts in
MDSCs. mechanism
While STAT3,
butnegatively
not miR-124,
can regulate
theexpression,
RUNXOR–RUNX1
axis in a network
positive feedback
concert
to promote
MDSC development
and suppressive
functions
during chronic
mechanism
and negatively
regulate miR-124
expression,
this regulatory
networkHCV
acts infection.
in concert to
promote MDSC development and suppressive functions during chronic HCV infection.
3.6. HCV-Associated Exosomes Regulate RUNXOR, RUNX1, and Suppressive Molecule Expressions in
3.6. HCV-Associated Exosomes Regulate RUNXOR, RUNX1, and Suppressive Molecule Expressions
MDSCs
in MDSCs
To determine whether HCV-associated exosomes (HCV-Exo) can induce the alterations we
To determine
whether
HCV-associated
exosomes
(HCV-Exo)
can induce
the alterations
we
observed
in RUNXOR,
RUNX1,
and suppressive
molecule
expressions
in MDSCs
during HCV
observed
in
RUNXOR,
RUNX1,
and
suppressive
molecule
expressions
in
MDSCs
during
HCV
infection, we isolated exosomes from the plasma of HCV subjects with high or low viral load (HCV
infection,
we isolated
exosomes
thehighplasma
ofHCV
HCVlowsubjects
with high and
or low
viral load
RNA
= 17,000,000
or 17,000,
named from
as HCV
-Exo and
-Exo, respectively)
HS (HS-Exo).
high -Exo and HCVlow -Exo, respectively) and HS
(HCV
RNA
=
17,000,000
or
17,000,
named
as
HCV
These exosomes were added to cultures of healthy PBMCs for five days, followed by the selection of
(HS-Exo).
Thesethe
exosomes
were added
to cultures
of healthy PBMCs
fiveisolated
days, followed
by
+ cells from
CD33
treated PBMCs.
Similar
to the observations
in CD33+for
cells
from HCV
+
+
theHS,
selection
of CD33
cells
fromthat,
the treated
PBMCs.
Similar
to the
observations
in CD33
cells
low-Exo induced
and
RT-qPCR
analysis
showed
while both
HCVhigh
-Exo and
HCV
RUNXOR
high -Exo and HCVlow -Exo
isolated
from
HCV
and
HS,
RT-qPCR
analysis
showed
that,
while
both
HCV
(Figure 5A) and RUNX1 (Figure 5B) expressions, only HCVhigh-Exo led to a significant increase in
high
induced
RUNXOR
and RUNX1
(Figure 5B)
led to a
high-Exo -Exo
both
RUNXOR
and (Figure
RUNX15A)
expressions
in treated
cells.expressions,
Moreover, only
HCVHCV
significantly
high -Exo
significant
increase
in
both
RUNXOR
and
RUNX1
expressions
in
treated
cells.
Moreover,
HCV
upregulated the expression levels of Arg1 (Figure 5C), iNOS (Figure 5D), STAT3 (Figure 5E), and
significantly
upregulated
thewhile
expression
levels of Arg1
(Figurelevels
5C), iNOS
(Figure
5D), STAT3
(Figure
5E),
ROS
production
(Figure 5F),
downregulated
miR-124
(Figure
5G). These
results
suggest
andHCV-Exo
ROS production
downregulated
miR-124
levels (Figure
5G).
These results
suggest
that
plays a(Figure
role in5F),
thewhile
differential
regulation
of RUNXOR,
RUNX1,
STAT3,
and miR-124
that
HCV-Exo
plays
a
role
in
the
differential
regulation
of
RUNXOR,
RUNX1,
STAT3,
and
miR-124
expressions during chronic HCV infection.
expressions during chronic HCV infection.

Figure 5. HCV-Exo or cytarabine treatment regulates lncRNA, miRNA, and mRNA expressions in
MDSCs
vitro. (A–G)
Expressions
of RUNXOR,
RUNX1,
Arg1,
iNOS, STAT3,
ROS, expressions
and miR-124inin
Figure
5. in
HCV-Exo
or cytarabine
treatment
regulates
lncRNA,
miRNA,
and mRNA
high -Exo or
CD33+ in
cells
treated
with
exosomes isolated
from plasma
HCV-infected
individuals
(HCV
MDSCs
vitro.
(A–G)
Expressions
of RUNXOR,
RUNX1,ofArg1,
iNOS, STAT3,
ROS, and
miR-124
in
low -Exo) and HS (HS-Exo). (H–K) Cytarabine treatment induces the expression levels of RUNXOR,
+
high
HCV
CD33 cells treated with exosomes isolated from plasma of HCV-infected individuals (HCV -Exo
+ cells.
low-Exo)
andand
STAT3
HS-CD33(H–K)
orArg1,
HCViNOS,
HS in
(HS-Exo).
Cytarabine treatment induces the expression levels of

RUNXOR, Arg1, iNOS, and STAT3 in HS-CD33+ cells.

3.7. Cytarabine Regulates RUNXOR and Immunosuppressive Molecules in Healthy CD33+ Cells
Cytarabine,
also known
as cytosine
arabinoside (Ara-C),
is in
anHealthy
antileukemic
drug that treats
3.7. Cytarabine
Regulates
RUNXOR
and Immunosuppressive
Molecules
CD33+ Cells
AML and has been shown to increase the expression of RUNXOR [29]. We used cytarabine as a
Cytarabine, also known as cytosine arabinoside (Ara-C), is an antileukemic drug that treats AML
tool to manipulate RUNXOR expression in CD33+ cells to investigate its role in MDSC development.
and has been shown to increase the expression of RUNXOR
[29]. We used cytarabine as a tool to
As shown in Figure 5H, treatment of healthy CD33+ cells with Cytarabine significantly increased
manipulate RUNXOR expression in CD33+ cells to investigate its role in MDSC development. As
RUNXOR expression. Notably, Cytarabine exposure also increased the expression of suppressive
shown in Figure 5H, treatment of healthy CD33+ cells with Cytarabine significantly increased
RUNXOR expression. Notably, Cytarabine exposure also increased the expression of suppressive
molecules Arg1, iNOS, and STAT3 (Figure 5I–K). These results further support the role of RUNXOR
in promoting MDSCs and their suppressive functions.
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3.8.Silencing
SilencingRUNXOR
RUNXORand
andRUNX1
RUNX1Expressions
ExpressionsReduce
ReduceMDSC
MDSCFrequencies
Frequenciesand
andSuppressive
SuppressiveFunctions
Functions
To
whether
silencing
RUNXOR
or RUNX1
expression
attenuates
HCV-induced
MDSC
Todetermine
determine
whether
silencing
RUNXOR
or RUNX1
expression
attenuates
HCV-induced
+ cells with +RUNXOR or RUNX1
expansion
and
immunosuppression,
we
transfected
HCV-derived
CD33
MDSC expansion and immunosuppression, we transfected HCV-derived CD33 cells with RUNXOR
siRNA,
followed
by measuring
MDSCs
and theof
expressions
of immunosuppressive
or RUNX1
siRNA,
followed the
by frequencies
measuring ofthe
frequencies
MDSCs and
the expressions of
molecules
in these cells.
Compared
to thecells.
control
siRNA, to
RUNXOR
andsiRNA,
RUNX1
siRNA significantly
immunosuppressive
molecules
in these
Compared
the control
RUNXOR
and RUNX1
−
+ cells
−
reduced
the frequencies
of HLA-DR
, immunosuppressive
cell subset within
CD33
siRNA significantly
reduced
the frequencies
of HLA-DR , immunosuppressive
cellthe
subset
within
the
(Figure
6A), (Figure
and concurrently
decreased the
levels ofthe
Arg1
(Figure
6B),
iNOS 6B),
(Figure
6C),
pSTAT3
CD33+ cells
6A), and concurrently
decreased
levels
of Arg1
(Figure
iNOS
(Figure
6C),
(Figure
6D),
and 6D),
ROSand
production
(Figure (Figure
6E). Silencing
RUNXOR
and RUNX1
also increased
the
pSTAT3
(Figure
ROS production
6E). Silencing
RUNXOR
and RUNX1
also increased
+
+
levels
of miR-124
expression
in CD33
cells
derived
from
HCV
the levels
of miR-124
expression
in CD33
cells
derived
from
HCVpatients
patients(Figure
(Figure6F).
6F).Importantly,
Importantly,
the
MFI
of of
IFN-γ
production
by autologous
CD4CD4
T cells
werewere
significantly
improved
after
thefrequency
frequencyand
and
MFI
IFN-γ
production
by autologous
T cells
significantly
improved
+ cells that
+
culturing
them
with
HCV-derived
CD33
were
transfected
with
RUNXOR
and
RUNX1
siRNA
after culturing them with HCV-derived CD33 cells that were transfected with RUNXOR and RUNX1
(Figure
results
indicate
inhibiting
the RUNXOR–RUNX1
pathway can
attenuate
siRNA 6G,H).
(FigureThese
6G,H).
These
resultsthat
indicate
that inhibiting
the RUNXOR–RUNX1
pathway
can
MDSC
differentiation
and suppressive
functions. functions.
attenuate
MDSC differentiation
and suppressive

Figure
Figure6.6.Silencing
SilencingRUNXOR
RUNXORor
orRUNX1
RUNX1inhibits
inhibitsthe
thedifferentiation
differentiationofofMDSCs
MDSCsand
andtheir
theirsuppressive
suppressive
+ cells reduces
+
functions.
(A)
Silencing
of
RUNXOR
or
RUNX1
in
HCV-CD33
the
maturation
of myeloidof
functions. (A) Silencing of RUNXOR or RUNX1 in HCV-CD33 cells reduces the maturation
−/low subset
+ ). (B–F) Silencing
+ decreases +
−/low
+
cells
(HLA-DR
in
CD33
RUNXOR
or
RUNX1
in
HCV-CD33
myeloid cells (HLA-DR
subset in CD33 ). (B–F) Silencing RUNXOR or RUNX1 in HCV-CD33
the
Arg1, iNOS
and pSTAT3
and
increases
(G,H) The(G,H)
percentage
and MFIand
of
decreases
the Arg1,
iNOS and
pSTAT3
andmiR-124
increasesexpression.
miR-124 expression.
The percentage
IFN-γ
is restored
in HCV-CD4
T cells following
incubation
with autologous
CD33+CD33
cells +
MFI ofproduction
IFN-γ production
is restored
in HCV-CD4
T cells following
incubation
with autologous
after
RUNXOR
or RUNX1
expression.
(I) IFN-γ
production
is suppressed
in CD4
cellsT
cellssilencing
after silencing
RUNXOR
or RUNX1
expression.
(I) IFN-γ
production
is suppressed
inTCD4
+ cells overexpressing RUNXOR.
following
incubation
with
autologous
HS-CD33
+
cells following incubation with autologous HS-CD33 cells overexpressing RUNXOR.

To
elucidate
the role
RUNXOR-regulated
MDSCs inMDSCs
T cell functions,
we overexpressed
Tofurther
further
elucidate
theofrole
of RUNXOR-regulated
in T cell
functions, we
+ cells and then co-cultured them with autologous CD4 T cells for three
RUNXOR
in
healthy
CD33
+
overexpressed RUNXOR in healthy CD33 cells and then co-cultured them with autologous CD4 T
days,
measuring
production
in activated
CD4 in
T cells.
As shown
Figure
IFN-γin
cells followed
for three by
days,
followedIFN-γ
by measuring
IFN-γ
production
activated
CD4 Tincells.
As 6I,
shown
production
was
significantly
suppressed.
These
results
support
a
role
for
RUNXOR
in
promoting
Figure 6I, IFN-γ production was significantly suppressed. These results support a role for RUNXOR
MDSC
immunosuppressive
effects on T celleffects
functions.
in promoting
MDSC immunosuppressive
on T cell functions.

4. Discussion
MDSCs have been shown to expand and inhibit host immune responses in multiple disease
models; however, the mechanisms of MDSC development during viral infection remain incompletely
understood. In this study, we demonstrate that: (1) the expressions of lncRNA RUNXOR and its
target gene RUNX1 are upregulated in MDSCs that accumulate in the peripheral blood of patients
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our previous
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findings
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(as depicted
in7),Figure
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in Figure
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RUNX1
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complexes, transcriptional regulators, or DNA methylation machinery [19–21]. LncRNAs can act
as scaffolds by recruiting activators or suppressors at target gene promoters in the nucleus and can
also epigenetically regulate gene transcription by regulating histone modifications and chromatin
remodeling. LncRNAs also act as a sponge for miRNAs in the cytoplasm and help modify gene
expression at the post-transcriptional level [35,36]. In our study, we found that RUNXOR and its
target protein RUNX1 can regulate the STAT3–miR-124 axis, thereby regulating the development and
suppressive functions of MDSCs during HCV infection. Notably, previous studies have shown that
HCV promotes STAT3 signaling to maintain chronic infection [46]. HCV induces STAT3 directly by
interacting with the HCV core protein [47], and indirectly through non-structural protein 5A (NS5A)
via ROS [48]. In current study, we show that STAT3 is regulated through the RUNXOR–RUNX1 axis, as
demonstrated by the RUNXOR–RUNX1 knockdown experiments (Figure 6D). In addition, our results
show that silencing STAT3 expression also reduced the levels of RUNXOR, RUNX1, Arg1, and iNOS
expressions (Figure 4I–L). Moreover, it has been reported that low miR-124 levels induced by HCV
core protein via DNMT1 promote ICC cell migration and invasion by targeting SMYD3 [49], indicating
the complexity of the host immune system. Here, our data suggest a regulatory loop involving the
RUNXOR–RUNX1 pathway and STAT3–miR-124 signaling in MDSC induction during HCV infection.
These new findings further support our previous studies, which link MDSC expansion to the induction
of STAT3–miR-124 pathway [17].
Our results suggest that RUNX1 is a target for positive regulation by RUNXOR. The RUNX1
gene is a Runt-related transcription factor, also known as AML1 (acute myelogenous leukemia 1),
that regulates the expression of several important hematopoietic regulator genes [50–54], including
genes regulating B-cell maturation [55], granulocyte differentiation, and megakaryocyte maturation [56].
The RUNX1 gene is frequently mutated in various hematological malignancies [57]. Both homozygous
and heterozygous mutations take place in the full-length of RUNX1 protein that results in either a
single amino-acid substitution in the DNA-binding domain or in a C-terminal truncation mutation,
leading to the removal of all or part of the transcriptional activation domain [58–61]. Expansion of
common myeloid progenitors and granulocyte-macrophage progenitor (GMP) pools were observed
under RUNX1 deficiency that was rescued by the inactivation of Hmga2 [62]. Similarly, an increase in
the susceptibility to AML development in conjunction with MLL-ENL and N-Ras in the absence of
RUNX1 supported the role of RUNX1 as a tumor-suppressor [63,64]. Recently, however, RUNX1 was
shown to function in a pro-survival manner in leukemogenesis, indicating the importance of RUNX1
expression in AML1-ETO and MLL-AF9 cells [65]. Taken together, these data indicate that RUNX1
acts in both an oncogenic and a tumor suppressor mode in a context-dependent manner [43,44,66–74].
In the current study, the pattern of RUNXOR expression is rather similar to that of the RUNX1 gene,
lending support to our notion that the RUNXOR–RUNX1 axis is important for MDSC development
and function.
How RUNXOR and RUNX1 control each other’s expression in a mutually exclusive manner is
unclear. Interactions among lncRNAs, miRNAs, and mRNAs have been described previously [75].
The multilayered complexity of RNA crosstalk and competition may arise due to lncRNA regulating
the expression of both neighboring genes and/or distant genes [76]. Interestingly, the RUNX genomic
regions overlap with RUNXOR, suggesting that the lncRNA RUNXOR participates in the regulation of
RUNX expression [28–30]. This study clearly shows that RUNXOR and RUNX1 regulate each other’s
expression to control STAT3–miR-124 expressions in MDSCs, which supports a recent report showing
that the STAT3–miR214 axis plays an essential role in MDSC development during HCV infection [17].
RUNX1 inhibits the expression of suppressor of cytokine signaling 3 (SOCS3), an important negative
feedback regulator of the STAT3 signaling pathway [77]. These findings suggest that RUNX1 regulates
STAT3 phosphorylation, in part through the modulation of SOCS3 expression [77,78]. Based on our
results, we conclude that the RUNXOR–RUNX1 axis plays an important role in controlling MDSC
expansion and suppressive functions by regulating the STAT3–miR-124 axis during HCV infection.
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The putative cooperation of the two ncRNAs, RUNXOR and miR-124, in MDSC development and
HCV pathogenesis warrants further investigation.
A growing list of lncRNAs have been identified as bona fide transcriptional regulators,
and many studies are investigating these noncoding transcripts as potential biomarkers and
therapeutic targets in human diseases. To our knowledge, this is the first report showing that
the RUNXOR–RUNX1–STAT3–miR-124 axis promotes MDSC development and immunosuppressive
functions during chronic HCV infection. Therefore, targeting this axis may provide a novel approach
for immunomodulation in conjunction with antiviral therapy to protect against the immune regulatory
effects of human viral infections.
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